- Conditions
- Study Adherence, Depressive Disorder
- Interventions
- Video-Chat Psychotherapy (VCP), Message-Based Psychotherapy (MBP), Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy, Message-Based Psychotherapy with Weekly Video-Chat Psychotherapy, High Monetary Incentive (HMI), Low Monetary and Alternative Incentive (LMAI)
- Behavioral
- Lead sponsor
- Talkspace
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 855
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Obesity
- Interventions
- Bariatric surgery
- Procedure
- Lead sponsor
- Ascension St. Vincent Carmel Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 414 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Carmel, Indiana
- Conditions
- Pulmonary Hypertension
- Interventions
- treprostinil sodium
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Congestive Heart Failure
- Interventions
- Implantable Hemodynamic Monitor, Angiotensin-Converting Enzyme Inhibitor, Angiotensin II Type 1 Receptor Blocker, sacubitril/valsartan
- Device · Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hearing Loss, Mixed, Hearing Loss, Conductive, Single-Sided Deafness, Bone Conduction
- Interventions
- Cochlear™ Osia® System (Osia® 2), Cochlear™ Osia® System (Osia® 3)
- Device
- Lead sponsor
- Cochlear
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Urothelial Carcinoma
- Interventions
- MRx0518, Avelumab 20 mg/mL Intravenous Solution (IV)
- Drug · Biological
- Lead sponsor
- 4D pharma plc
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Irvine, California • Dallas, Texas • Houston, Texas
- Conditions
- Graft Versus Host Disease
- Interventions
- Visilizumab, Tacrolimus, Methotrexate, Antithymocyte globulin (ATG)
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Opioid Use Disorder
- Interventions
- Buprenorphine, Oxycodone
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Amyotrophic Lateral Sclerosis, Respiratory Muscle Weakness
- Interventions
- High Frequency Chest Wall Oscillation, Mechanical insufflation/exsufflation
- Device
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- HIV Infections, Renal Transplant Rejection
- Interventions
- BIC/F/TAF 50Mg-200Mg-25Mg Tablet
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Parkinson Disease, Huntington Disease
- Interventions
- Group Drumming Music Therapy
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- HIV -1 Infection
- Interventions
- TMB-365, TMB-380, Baseline ART
- Drug
- Lead sponsor
- TaiMed Biologics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 10
- States / cities
- San Francisco, California • Fort Lauderdale, Florida • Ft. Pierce, Florida + 7 more
- Conditions
- Other Infectious Diseases
- Interventions
- Cefepime, Ceftolozane, Laboratory Biomarker Analysis, Meropenem, Piperacillin-Tazobactam, Tazobactam
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HIV Infections
- Interventions
- Emtricitabine (FTC), Tenofovir disoproxil fumarate (TDF), Efavirenz (EFV), Truvada
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Candidiasis, Invasive, Candidemia, Mycoses
- Interventions
- Isavuconazole, Caspofungin, Voriconazole
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Palm Desert, California • Sacramento, California + 15 more
- Conditions
- Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Renal Cell Carcinoma, Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer
- Interventions
- P-MUC1C-ALLO1 CAR-T cells, Rimiducid
- Biological · Drug
- Lead sponsor
- Poseida Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2039
- U.S. locations
- 14
- States / cities
- Irvine, California • Los Angeles, California • San Diego, California + 11 more
- Conditions
- Pregnancy, Sexually Transmitted Diseases
- Interventions
- Interactive multimedia platform, Intervention arm counseling, Standard of care counseling
- Behavioral
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 14 Years to 19 Years · Female only
- Enrollment
- 709 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Acute Gout
- Interventions
- Canakinumab 150 mg, Triamcinolone acetonide 40 mg, Placebo to canakinumab, Placebo to triamcinolone acetonide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 96
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Foley, Alabama + 81 more
- Conditions
- Alzheimer's Disease
- Interventions
- Remternetug (IV), Remternetug (SC), Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 1,667 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 73
- States / cities
- Chandler, Arizona • Canoga Park, California • Carlsbad, California + 66 more
- Conditions
- Cancer
- Interventions
- Atezolizumab, Bevacizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- Not listed
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 44
- States / cities
- Scottsdale, Arizona • Los Angeles, California • San Marcos, California + 36 more
- Conditions
- Smoking Cessation, Harm Reduction, E-Cig Use, Cigarette Smoking, Tobacco Dependence, Tobacco Use Cessation
- Interventions
- JUUL
- Other
- Lead sponsor
- Rose Research Center, LLC
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Charlotte, North Carolina • Raleigh, North Carolina
- Conditions
- Pancreas Cancer, Relapse, Resistant Cancer
- Interventions
- iC9-CAR.B7-H3 T cell infusion
- Biological
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Coronary Artery Disease
- Interventions
- clopidogrel 75 mg, Prasugrel 5 mg
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Graft Vs Host Disease
- Interventions
- Cyclophosphamide, Abatacept, Tacrolimus
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York